注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Biomea Fusion Inc是一家处于临床前阶段的生物制药公司。该公司专注于发现、开发和商业化不可逆转的小分子药物,用于治疗基因定义的癌症患者。该公司已经建立了聚变系统发现平台,以推进不可逆转的小分子候选产品管道。该公司的主要候选产品BMF-219是一种口服生物利用、有效和选择性的不可逆美宁抑制剂,menin是一种重要的转录调节因子,已知在多种癌症的致癌信号传导中发挥直接作用。该公司正在开发BMF-219,用于治疗依赖menin的液体和固体肿瘤,包括含有混合谱系白血病(MLL)融合蛋白的白血病。该公司还正在推进其他临床前不可逆项目,以治疗某些癌症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Ramses M. Erdtmann | 59 | 2017 | Co-Founder, President, COO & Director |
Thomas Andrew Butler | 41 | 2017 | Co-Founder, Chairman & CEO |
Michael J. M. Hitchcock | 73 | 2021 | Independent Director |
Sumita Ray | 49 | 2021 | Independent Director |
Eric M. Aguiar | 61 | 2020 | Independent Lead Director |
Bihua Chen | 55 | 2020 | Independent Director |
David D. Smith | 53 | 2022 | Member of Scientific Advisory Board |
Rohit Kulkarni | - | - | Member of Scientific Advisory Board |
Bruce H. Lipshutz | - | 2022 | Member of Scientific Advisory Board |
Jeremy Pettus | - | 2023 | Member of Scientific Advisory Board |
Elizabeth A. Faust | 58 | 2022 | Independent Director |
Xianxin Hua | - | 2022 | Member of Scientific Advisory Board |
Margaret A. Tempero | - | 2022 | Member of Scientific Advisory Board |
David B. Ball | - | 2022 | Member of Scientific Advisory Board |
Jeffrey Rubnitz | - | 2022 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核